Arrowhead Research Corporation Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B
Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it presented new data on ARC-520, its clinical candidate for the treatment of chronic hepatitis B virus, at the 2013 AASLD Annual Meeting.
Help employers find you! Check out all the jobs and post your resume.